However, expression and structural clustering analysis suggest that the effects of the compound in normal cells have similarity with agents targeting the PI3K/AKT pathway, whereas in cancer cells, the effects diverged from other well characterized cell cycle inhibitors. The gene discussed is AKT1; the disease is cancer.